26 results about "Bladder Tissue" patented technology

The invention belongs to the field of biomedicine, and particularly relates to a 3D bio-printed vascularization-promoting bladder patch and a preparation method thereof. The preparation method comprises the following steps: polymerizing prepared GelMA and Laponite to prepare GelMA-Laponite hydrogel, then mixing and printing the GelMA-Laponite hydrogel and seed cells on a bladder acellular matrix by using a 3D biological printing machine to form a GelMA-Laponite stent with a three-dimensional space structure, and crosslinking the stent by using ultraviolet light to obtain the double-layer vascularized bladder patch. The construction level of the tissue-engineered bladder patch is expected to be improved, the vascularization problem of the tissue-engineered bladder graft is solved, and a good theoretical basis and technical support are laid for promoting the clinical application process of bladder tissue engineering.

The purpose of the present invention is to provide a novel medical application using pluripotent stem cells in regenerative medicine. The present invention provides a cell formulation and pharmaceutical composition that are for amelioration and therapy for frequent urination and bladder pain caused by the inflammation of the bladder and that contain SSEA-3 positive pluripotent stem cells isolated from cultured mesenchymal cells or a mesenchymal tissue of a living organism. The cell formulation according to the present invention is considered to be based on a mechanism in which, for example, Muse cells are administered against interstitial cystitis having the abovementioned disorders to be successfully engrafted into affected bladder tissue, whereby the disorders are ameliorated and treated.

The application provides a urine exosome-based bladder cancer gene detection system and application, and relates to the technical field of biological detection. Through the cooperative application of the internal reference gene and the diagnosis model, the application provides a reliable endogenous quality control standard for the bladder tissue-derived exosome in the urine exosome sample; meanwhile, the application realizes non-invasive, accurate, rapid screening, diagnosis, prognosis and recurrence monitoring of bladder cancer, lays a key technical foundation and detection tool for the urine exosome-based molecular diagnosis of bladder cancer, and has important clinical transformation value and application prospect.

The utility model provides a vagina and bladder pressing plate, which relates to the technical field of vagina pressing plates, and comprises a handle A, a head end and a tail end, one end of the handle A is provided with the head end, the other end of the handle A is provided with the tail end, the head end is a butterfly-shaped baffle plate which is symmetrical along the central axis of the handle A, and the tail end is a semicircular separating plate which is symmetrical along the central axis of the handle A; the upper portion and the lower portion of the head end are each of a wing-shaped structure, the transverse width of the upper portion is larger than that of the lower portion, and the problem that when a pubis descending branch anchoring point is sutured in an existing operation, a tool for effectively and safely separating a vaginal bladder gap and pressing bladder tissue beside the urethra lacks is solved.

The invention provides a method of treating interstitial cystitis that applies therapeutic exomes to the bladder of a patient through intravesical administration. Unlike the intravesical administration of stem cells, the intravesical administration of exosomes permits a therapeutic amount of paracrine-active growth factors and cytokines to be applied to bladder tissue before they can voided by urination.

The present invention provides a bladder cancer gene mutation prediction system based on deep learning, comprising: a histopathological image acquisition module for acquiring original tissue histopathological images to be measured; a preprocessing module for preprocessing the original tissue histopathological images to be measured by using the HE staining method and a whole slide imaging scanner to obtain a WSI of a bladder tissue with HE staining; a cloud server module for calling a deep learning prediction model for bladder cancer to respectively predict the gene expression status, gene methylation status and gene mutation status of bladder cancer for the WSI, and generating corresponding prediction results; and a report generation module for automatically generating an auxiliary diagnosis report for bladder cancer gene mutation prediction according to the corresponding prediction results and feeding it back to a specified terminal.

The invention relates to the technical field of medical analysis and evaluation, in particular to a spinal cord injury patient neurogenic bladder function state evaluation system which comprises a basic information acquisition module, a bladder function dynamics examination and evaluation module, a bladder tissue detection and analysis module and a bladder function state evaluation module. Basic information of a spinal cord injury patient is obtained based on a basic information acquisition module; urodynamic examination information of a spinal cord injury patient is obtained by using a bladder function dynamic examination and evaluation module, and the above modules are combined with the urodynamic examination information and basic information to obtain a bladder dynamic evaluation result; the bladder tissue detection and analysis module obtains tissue detection information of a spinal cord injury patient, and the module obtains a bladder tissue analysis result according to the tissue detection information and basic information; and the bladder function state evaluation module comprehensively evaluates the neurogenic bladder function state of the patient according to the basic information, the bladder dynamics evaluation result and the bladder tissue analysis result.

Provided herein are materials and methods related to scaffolds and uses thereof. In some embodiments, provided herein are poly (octamethylene-octanol citrates) (POOC) scaffolds with native mechanical properties that are comparable to urinary bladder tissue. In some embodiments, provided herein are methods for the synthesis of POOC scaffolds with native mechanical properties that are comparable to urinary bladder tissue by including octanol in the polycondensation synthesis of POC. In some embodiments, provided herein are methods of use of the disclosed scaffolds, including for urinary bladder tissue regeneration.

The need for improved drug delivery methods and systems for treating bladder cancer remains. It exists as such. [Solution] Gemcitabine is administered intravesically into the bladder of patients requiring treatment for bladder cancer, and then absorbed into the bladder tissue. A sustained concentration of gemcitabine sufficient to produce the above-mentioned therapeutically effective concentration By obtaining mucitabine in the urine of the bladder, the above patients can be administered gemcitabine. A drug delivery device and method are provided. In an embodiment, local delivery into the bladder of the patient. The administration is based on the average dose of gemcitabine (FBE) mentioned above, ranging from 1 mg / day to approximately 300 mg / day. That is the case.

The invention relates to the technical field of genes and medical engineering, in particular to an escherichia coli targeted culture method, and further discloses application of the escherichia coli targeted culture method in the field of mucosa repair. According to the Escherichia coli targeted culture method, in order to improve the colonization ability of EcN to damaged bladder tissue, the adhesive EcN is selected through a bacterial binding and culture (BBC) strategy inspired by further bacterial domestication, so that the adhesive EcN specifically bound with inflammatory bladder epithelial cells is screened, and the specific binding capacity of the EcN to the damaged bladder tissue is improved. The EcN can target and colonize inflammatory bladder tissue for a long time through one-time therapy.

The present application relates to the field of biotechnology, in particular to human bladder tissue digestion solution and application thereof.The digestion method of the present application can dissociate human bladder tissue cells while keeping the cell viability at more than 90%, and the amount of harvested cells is also obviously improved.Sufficient cell amount is the prerequisite for optimization treatment such as red blood cell lysis and dead cell removal.The single cell suspension obtained by the method has high viability, low clumping rate, high nucleated rate and less impurities, which can provide a basis for obtaining high-quality gene expression data in human bladder tissue single cell sequencing experiment.The present application can quickly obtain human bladder tissue primary cell suspension (sufficient cell amount, high viability, low clumping rate and less impurities) meeting the requirements of single cell experiment within 2-4 hours.

Disclosed are methods for regenerating bladder tissue. More specifically, disclosed are methods of regenerating bladder tissue by administering aryl hydrocarbon receptor effectors to a subject in need thereof.

The invention relates to the technical field of traditional Chinese medicines, in particular to a foundation-consolidating and life-prolonging pill for improving frequent urination at night and a preparation method of the foundation-consolidating and life-prolonging pill. The invention discloses a foundation strengthening and life prolonging pill for improving frequent micturition at night. The traditional Chinese medicine composition comprises the following components in parts by weight: 3-12 parts of ginseng, 5-15 parts of Chinese yam, 3-12 parts of dogwood, 2-14 parts of akebiaquinata, 3-10 parts of exocarpium benincasae, 2-10 parts of pericarpium arecae, 1-8 parts of semen boitae, 3-12 parts of radix achyranthis bidentatae, 1-7 parts of deer-horn glue, 1-7 parts of tortoise-plastron glue, 5-16 parts of pyrrosia lingua, 0.5-5 parts of liquorice, 3-10 parts of morinda officinalis, 4-15 parts of mantis egg-case, 3-10 parts of fructus alpiniae oxyphyllae, 6-20 parts of fructus rosae laevigatae, 6-20 parts of raspberry and 6-20 parts of The foundation-consolidating and life-prolonging pill does not cause pathological damage to drug metabolism visceral liver tissue, urine metabolism and regulation of visceral kidney, adrenal gland and bladder tissue. According to a high-dose group of the foundation strengthening and life prolonging pills, the urination latency period can be remarkably prolonged, the urine volume and weight ratio and the total excretion rate can be reduced, the urination latency period of the foundation strengthening and life prolonging pill is prolonged to 47.88 min from 34.38 min, the urine volume and weight ratio is reduced to 29.86 mL / kg from 44.81 mL / kg, and the total excretion rate is reduced to 62.86% from 81.37%.

The invention relates to the use of epidermal growth factor for the manufacture of a medicament for the treatment of interstitial cystitis. The "epidermal growth factor" (EGF) of the invention can be used to manufacture an excellent medicament for interstitial cystitis. The medicament has a composition that includes an active ingredient, adjuvant, dispersant, wetting agent, and / or suspension agent. The carrier of the epidermal growth factor is water, colloid, hyaluronic acid, natural oils, and / or glucose. The medicament serves to reduce urinary frequency. The medicament serves to restore bladder elasticity. The medicament serves to reduce cystitis. The medicament serves to increase the antioxidant capacity in bladder tissue.The present invention proposes a novel effect of epidermal growth factor, which can be used to treat interstitial cystitis and to repair the bladder mucosa and exhibits excellent efficacy.

The invention belongs to the technical field of biological medicine and molecular biology, and provides application of S100A8 in preparation of a medicine for preventing / treating bladder infection after spinal cord injury. The S100A8 can be used as a prevention target of bladder infection after potential spinal cord injury, and after the S100A8 is perfused into the bladder, the colony count of the bladder tissue is obviously reduced, so that the S100A8 has an infection prevention effect; meanwhile, the damage repair capacity of the bladder epithelium is remarkably improved, the compound can be used as a prevention / treatment target spot for preventing bladder infection after spinal cord injury, and a new thought is provided for clinical prevention and treatment of bladder infection after spinal cord injury.

The invention provides a method of treating interstitial cystitis that applies therapeutic exomes to the bladder of a patient through intravesical administration. Unlike the intravesical administration of stem cells, the intravesical administration of exosomes permits a therapeutic amount of paracrine-active growth factors and cytokines to be applied to bladder tissue before they can voided by urination.

A closed extension tube for a catheter comprises an extension tube body, a catheter and a urine bag, and is characterized in that one end of the extension tube is communicated with the urine bag, and the other end of the extension tube is provided with a telescopic rubber sleeve section; the end part of the telescopic rubber sleeve section is a joint pipe, and is sleeved with one end of the urinary catheter through the joint pipe; a valve is arranged in the joint pipe; according to the extension tube, the length of the adopted catheter can be shortened, and a guide wire can penetrate into the catheter conveniently, so that the catheter can enter the bladder more conveniently; the pulling between the catheter and the body of a patient can be reduced, the pressure of the catheter on urethra and bladder tissues is reduced, and the risk of urethra injury is reduced; the position of the catheter can be better adjusted, the discomfort of a patient is reduced, and the comfort of the patient is improved; the urethral catheterization bag can be managed and replaced more easily, and the situation that the urethral catheterization bag is moved frequently or the urethral catheter falls off is reduced.

Drug delivery devices and methods are provided for administering gemcitabine to a patient in need of bladder cancer treatment by intravesical administration of gemcitabine into the patient's bladder to achieve a sustained urinary concentration of gemcitabine in the bladder sufficient to produce a therapeutically effective concentration of gemcitabine in the bladder tissues. In embodiments, the local administration into the patient's bladder is in an average amount of from 1 mg / day to about 300 mg / day of gemcitabine (FBE).

The invention belongs to the technical field of exosome application, and discloses application of a sarcodon aspratus exosome in preparation of a medicine for treating interstitial cystitis. The prepared sarcodon aspratus exosome is perfused into the bladder of a rat with interstitial cystitis, and it is found that the sarcodon aspratus exosome can significantly improve urination disorder of the model rat and relieve symptoms of interstitial cystitis. In addition, the invention also finds that (1) the sarcodon aspratus exosome can obviously reduce the expression of IL-1beta, IL-6, MCP-1, CXCL-1, ICAM-1 and BAX in the bladder tissue; (2) the sarcodon aspratus exosome can significantly reduce the activation number of mast cells and inhibit degranulation of the mast cells; and (3) the sarcodon aspratus exosome can significantly improve epithelial cell apoptosis. The research shows that the sarcodon aspratus exosome can be used for treating interstitial cystitis. The research provides a new idea for the treatment of interstitial cystitis.

The application provides a urine exosome-based bladder cancer gene detection system and application, and relates to the technical field of biological detection. Through the cooperative application of the internal reference gene and the diagnosis model, the application provides a reliable endogenous quality control standard for the bladder tissue-derived exosome in the urine exosome sample; meanwhile, the application realizes non-invasive, accurate, rapid screening, diagnosis, prognosis and recurrence monitoring of bladder cancer, lays a key technical foundation and detection tool for the urine exosome-based molecular diagnosis of bladder cancer, and has important clinical transformation value and application prospect.

The invention relates to the technical field of medical instruments, in particular to a flexible strain sensor and a bladder capacity monitoring system.The flexible strain sensor is attached to the surface of the bladder and used for generating deformation according to expansion or contraction of the bladder wall and converting the deformation into an electric signal; the flexible strain sensor comprises a flexible substrate layer, a conductive material layer and a packaging layer, the flexible substrate layer is made of platinum-catalyzed organic silicon rubber (Ecoflex-0050), the modulus of the flexible substrate layer is matched with that of bladder tissue, the thickness of the flexible substrate layer is 500 microns, and the flexible substrate layer can generate synchronous deformation along with expansion and contraction of the bladder; the conductive material layer is prepared by mixing a carbon nanotube (CNT) and Ecoflex-0050 according to the proportion of 5wt%, the thickness of the conductive material layer is 100nm, and the conductive material layer is uniformly coated on the surface of the substrate layer to form a stretchable conductive network; the material of the packaging layer is Ecoflex-0050, and the thickness of the packaging layer is 200 [mu] m. The flexible strain sensor and the bladder capacity monitoring system provided by the invention aim to meet the requirements of good biocompatibility, high sensitivity and real-time bladder capacity detection.

Drug delivery devices and methods are provided for administering gemcitabine to a patient in need of treatment of bladder cancer by intravesically administering gemcitabine into the bladder of the patient to achieve a sustained concentration of the gemcitabine in urine in the bladder sufficient to produce a therapeutically effective concentration of the gemcitabine in the tissues of the bladder. In embodiments, the local administration into the patient's bladder is at a mean average amount of from 1 mg / day to about 300 mg / day of the gemcitabine (FBE).

Drug delivery devices and methods are provided for administering gemcitabine to a patient in need of treatment of bladder cancer by intravesically administering gemcitabine into the bladder of the patient to achieve a sustained concentration of the gemcitabine in urine in the bladder sufficient to produce a therapeutically effective concentration of the gemcitabine in the tissues of the bladder. In embodiments, the local administration into the patient's bladder is at a mean average amount of from 1 mg / day to about 300 mg / day of the gemcitabine (FBE).

The invention belongs to the technical field of exosome application, and discloses a triptolide-loaded nano co-delivery drug delivery carrier and application thereof in preparation of drugs for treating interstitial cystitis. The triptolide-loaded nano co-delivery drug delivery carrier is used for interstitial cystitis model animals, and the following changes are observed: 1, the sensitivity of the model animals to stimulation is reduced; 2, the urination frequency of model animals is reduced, and the urination volume of words is increased; 3, the number of red blood cells in urine of the model animal is reduced; 4, bladder tissue hyperemia is relieved, and the size is reduced; and 5, the expression of inflammatory factors IL-6, MCP-1, ICAM-1 and BAX is obviously reduced. Therefore, it can be determined that the triptolide-loaded nano-co-delivery drug delivery carrier is used for treating interstitial cystitis. According to the research, the application range of the triptolide is expanded, and the triptolide is combined with the exosome to be used for treating the interstitial cystitis, so that a new thought is provided for treating the interstitial cystitis.

Devices and methods for delivering treatment fluids or particulates such as, stem cells, drugs, Botox and like, to an inner lining of a bladder for treatment of urinary tract disorders, including over-active bladder. A balloon delivery system can include an inflation balloon having a plurality of micro-needles configured to pierce and otherwise puncture an inner bladder wall so as to deliver the treatment fluid to bladder tissue. The treatment fluid can be directly injected into the bladder tissue using the micro needles. Alternatively, the micro needles can be fabricated of bioabsorbable or bioresorbable materials such that the micro needles can remain embedded within the bladder tissue to deliver the treatment fluid or particulate.

The invention discloses a mouse reversible ureteral obstruction model and a construction method thereof, and the construction method comprises the following steps: carrying out anesthesia treatment on a mouse, fixing the supine position of the mouse, and carrying out skin preparation disinfection; cutting the middle of the lower abdomen of the mouse, removing the bladder out of the body, and exposing a ureter area and the joint of the lower end of the free ureter and the ureter bladder; the bladder tissue below the ureter bladder connecting position is ligated; sewing and closing abdominal muscles and skin by adopting a suture line; according to the construction method disclosed by the invention, through setting of a specific construction method, an obstruction region can be formed in a mouse bladder region, and the ureter cannot be obviously damaged, so that the obstruction success rate of the model can reach 100%, and the success rate of a recanalization operation can reach 90% or above.